NBTX

Nanobiotix S.A. is a biotechnology company in the healthcare sector. The company has a market capitalization of $1.01 billion and generates revenue of approximately $10.16 million (TTM). With 103 employees, Nanobiotix operates on a relatively small scale. The financial health of Nanobiotix is marked by negative profitability metrics. The company's gross margin stands at 100%, while the operating margin and profit margin are significantly lower at 3.1% and 0.0%, respectively. Net income (TTM) was -$51,643,000, indicating substantial losses. Return on Assets (ROA) is -41.6%, suggesting that the company's assets may not be generating sufficient revenue to cover costs. The balance sheet reveals a relatively high debt level of $51.24 million and a modest cash position of $28.82 million. Valuation metrics provide insight into Nanobiotix's stock price performance. With a forward P/E ratio of 25.69, the company is trading at a premium valuation. Revenue growth has been substantial, with an annual increase of 186.8%. However, this growth may be reflected in the stock price rather than being sustainable or indicative of future earnings growth. Dividend payments are not made by the company, as the payout ratio is 0.0%.